June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

June 06, 2025

FDA Monthly Round-up: Key May Updates

May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.

Conexiant

June 04, 2025

Is ‘PCOS’ Due for a Rename?

A global survey reveals strong support for renaming PCOS, citing that the current term misrepresents the condition’s full range of reproductive, metabolic, and psychological features.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 22, 2025

At-Home HPV Test Matches Clinic Accuracy

Researchers found that an at-home self-collection device for HPV testing demonstrated high accuracy and safety, matching clinician-collected results for cervical cancer screening.

Conexiant

January 16, 2025

Algorithm Improves Diagnosis of Uterine Lesions

"The preoperative 3-class diagnostic algorithm and risk class system can stratify women according to risk of malignancy."

Conexiant

October 28, 2024

Single Swab Approach Assesses Co-Occurring Vaginal Infections

A recent study reveals that 80% of women with STIs may have bacterial vaginosis, highlighting the potential benefits of simultaneous STI and vaginitis testing in clinical practice.

Conexiant

November 14, 2024

Can Botox Ease Chronic Pelvic Pain?

A recent study assessed the efficacy of Botulinum Toxin A injections in conjunction with pelvic floor muscle therapy for women with chronic pelvic pain, revealing interesting insights into its effectiveness compared to a placebo.

Conexiant

December 10, 2024

Hormone Therapy Risks Vary: Tibolone Linked to Arterial Events

Recent study links tibolone use in menopausal hormone therapy to a 52% increased cardiovascular disease risk, emphasizing the need for tailored hormone therapy approaches and further research in BMJ.

Conexiant